Videocapsule Endoscopy in Lynch Syndrome
NCT: NCT05704010 · RECRUITING
Brief Summary
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2. These pathogenic variants confer a higher risk of developing colorectal and other cancers, including small bowel cancer. The risk of developing a small bowel adenocarcinoma is about 100 times higher compared to individuals without Lynch syndrome, and the lifetime risk of small bowel cancer is estimated at 4,2%. The diagnosis of a small bowel cancer depends on videocapsule endoscopy (VCE). This device is swalled so that it can record images of the small bowel, which are then stored on a wearable device for about 8 hours. The capsule is then expelled in the feces while the images are transferred to a computer to be analysed. To date, there is conflicting evidence on the efficacy of small bowel cancer screening with VCE Rationale: this registry study will collect prospective data from patients with LS undergoing VCE Aim: evaluate the incidence of neoplastic and pre-neoplastic lesions in patients with LS during a VCE-based small bowel cancer screening study Design: this is a multicentric, observational study that analyzes data from diagnostic techniques already approved. Patients will not undergo diagnostic procedures beyond what would be recommended by clinical practice.
Frequently Asked Questions
What is Videocapsule Endoscopy in Lynch Syndrome?
Videocapsule Endoscopy in Lynch Syndrome is a clinical trial registered under NCT05704010. Current status: RECRUITING.
What is the status of NCT05704010?
The current status of NCT05704010 (Videocapsule Endoscopy in Lynch Syndrome) is: RECRUITING.
When did Videocapsule Endoscopy in Lynch Syndrome start?
Videocapsule Endoscopy in Lynch Syndrome started on 2018-11-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.